Literature DB >> 35190359

Relationship between atherogenic index of plasma and stent thrombosis in patients with acute coronary syndrome.

Özge Özcan Abacıoğlu1, Arafat Yıldırım1, Nermin Yıldız Koyunsever1, Mine Karadeniz2, Salih Kılıç1.   

Abstract

OBJECTIVE: Stent thrombosis (ST) is an uncommon but serious complication in patients undergoing percutaneous coronary intervention (PCI). This study aimed to investigate the effect of atherogenic index of plasma (AIP) on ST.
METHODS: Among the 10,258 patients who underwent coronary angiography between January 2018 and December 2020, 239 patients who underwent PCI with the diagnosis of acute coronary syndrome (ACS) due to ST were included as the study group (ST group) and 459 patients who underwent percutaneous intervention for ACS and did not have any in-stent lesion as the control group (non-ST group). ST classification was done according to the Academic Research Consortium definition.
RESULTS: The mean age of the patients was 63.3±10.6 years (483 male, 69.2%). The groups were similar in terms of characteristic properties, comorbidities, and the drugs being used (p>0.05 for all). Drug eluting stents were used in 86.5% of the patients. In the ST group, the median time from stent implantation to thrombosis was 285 days. Mean AIP and the ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) were statistically significantly higher in the ST group than in the controls (p<0.001 and p=0.018, respectively), and a positive correlation was observed between time from stent implantation to thrombosis and AIP and TG/HDL-C (rS=0.229, p=0.010 and rS=0.222, p=0.010, respectively). Multivariate logistic regression analysis revealed that stent length, prior ST elevation myocardial infarction, TG/HDL-C, and AIP were independent predictors of ST.
CONCLUSION: AIP is an easy calculable biomarker, and the performance of AIP to predict ST is better than TG/HDL-C.

Entities:  

Mesh:

Year:  2022        PMID: 35190359      PMCID: PMC8878917          DOI: 10.5152/AnatolJCardiol.2021.193

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


  32 in total

1.  Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents.

Authors:  Laura Mauri; A James O'Malley; Jeffrey J Popma; Jeffrey W Moses; Martin B Leon; David R Holmes; Paul S Teirstein; Donald E Cutlip; Dennis Donahoe; Richard E Kuntz
Journal:  Am J Cardiol       Date:  2005-05-15       Impact factor: 2.778

2.  Late thrombosis of a drug-eluting stent presenting in the perioperative period.

Authors:  Duncan G de Souza; Victor C Baum; Natalie M Ballert
Journal:  Anesthesiology       Date:  2007-05       Impact factor: 7.892

Review 3.  Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.

Authors:  Anil Pandit; Smith Giri; Fayaz Ahmad Hakim; F David Fortuin
Journal:  Catheter Cardiovasc Interv       Date:  2014-05-06       Impact factor: 2.692

4.  Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting.

Authors:  Javaid Iqbal; Wael Sumaya; Victoria Tatman; Yasir Parviz; Allison C Morton; Ever D Grech; Stephen Campbell; Robert F Storey; Julian Gunn
Journal:  EuroIntervention       Date:  2013-05-20       Impact factor: 6.534

5.  White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry).

Authors:  Binita Shah; Usman Baber; Stuart J Pocock; Mitchell W Krucoff; Cono Ariti; C Michael Gibson; Philippe Gabriel Steg; Giora Weisz; Bernhard Witzenbichler; Timothy D Henry; Annapoorna S Kini; Thomas Stuckey; David J Cohen; Ioannis Iakovou; George Dangas; Melissa B Aquino; Samantha Sartori; Alaide Chieffo; David J Moliterno; Antonio Colombo; Roxana Mehran
Journal:  Circ Cardiovasc Interv       Date:  2017-09       Impact factor: 6.546

Review 6.  Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up.

Authors:  Abhishek Sharma; Sahil Agrawal; Aakash Garg; Ajay Vallakati; Carl J Lavie; Gerald Helft
Journal:  Catheter Cardiovasc Interv       Date:  2017-05-30       Impact factor: 2.692

Review 7.  Hyperlipidemia as a risk factor for cardiovascular disease.

Authors:  Robert H Nelson
Journal:  Prim Care       Date:  2012-12-04       Impact factor: 2.907

8.  The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization.

Authors:  Ke Wan; Jianxun Zhao; Hao Huang; Qing Zhang; Xi Chen; Zhi Zeng; Li Zhang; Yucheng Chen
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

9.  Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.

Authors:  Jan Borén; M John Chapman; Ronald M Krauss; Chris J Packard; Jacob F Bentzon; Christoph J Binder; Mat J Daemen; Linda L Demer; Robert A Hegele; Stephen J Nicholls; Børge G Nordestgaard; Gerald F Watts; Eric Bruckert; Sergio Fazio; Brian A Ference; Ian Graham; Jay D Horton; Ulf Landmesser; Ulrich Laufs; Luis Masana; Gerard Pasterkamp; Frederick J Raal; Kausik K Ray; Heribert Schunkert; Marja-Riitta Taskinen; Bart van de Sluis; Olov Wiklund; Lale Tokgozoglu; Alberico L Catapano; Henry N Ginsberg
Journal:  Eur Heart J       Date:  2020-06-21       Impact factor: 29.983

10.  Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy.

Authors:  Krishnankutty Sudhir; James B Hermiller; Joanne M Ferguson; Charles A Simonton
Journal:  ISRN Cardiol       Date:  2013-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.